These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33259228)

  • 21. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease.
    Lasseter HC; Provost AC; Chaby LE; Daskalakis NP; Haas M; Jeromin A
    Cytokine X; 2020 Jun; 2(2):100027. PubMed ID: 33604555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma.
    Dysinger M; Ma M
    AAPS J; 2018 Oct; 20(6):106. PubMed ID: 30280286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-binding assays: risk of using a platform supported by a single vendor.
    Yohrling J
    Bioanalysis; 2009 Jun; 1(3):629-36. PubMed ID: 21083158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid, automated, parallel quantitative immunoassays using highly integrated microfluidics and AlphaLISA.
    Yu ZT; Guan H; Cheung MK; McHugh WM; Cornell TT; Shanley TP; Kurabayashi K; Fu J
    Sci Rep; 2015 Jun; 5():11339. PubMed ID: 26074253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colloidal nanomaterial-based immunoassay.
    Teste B; Descroix S
    Nanomedicine (Lond); 2012 Jun; 7(6):917-29. PubMed ID: 22734642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of a low-affinity peptide for the detection of cystatin C in a fast homogeneous immunoassay.
    Dobslaff K; Zscharnack K; Kreisig T; Zuchner T
    Amino Acids; 2016 Feb; 48(2):479-86. PubMed ID: 26403846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanobodies and nanocrystals: highly sensitive quantum dot-based homogeneous FRET immunoassay for serum-based EGFR detection.
    Wegner KD; Lindén S; Jin Z; Jennings TL; el Khoulati R; van Bergen en Henegouwen PM; Hildebrandt N
    Small; 2014 Feb; 10(4):734-40. PubMed ID: 24115738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of an ultra-sensitive Simoa assay to enable GDF11 detection: a comparison across bioanalytical platforms.
    Myzithras M; Li H; Bigwarfe T; Waltz E; Gupta P; Low S; Hayes DB; MacDonnell S; Ahlberg J; Franti M; Roberts S
    Bioanalysis; 2016 Mar; 8(6):511-8. PubMed ID: 26917343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays.
    Dickson EF; Pollak A; Diamandis EP
    J Photochem Photobiol B; 1995 Jan; 27(1):3-19. PubMed ID: 7699520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
    Findlay JW; Smith WC; Lee JW; Nordblom GD; Das I; DeSilva BS; Khan MN; Bowsher RR
    J Pharm Biomed Anal; 2000 Jan; 21(6):1249-73. PubMed ID: 10708409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme inhibitor screening using a homogeneous proximity-based immunoassay for estradiol.
    Kokko L; Johansson N; Lövgren T; Soukka T
    J Biomol Screen; 2005 Jun; 10(4):348-54. PubMed ID: 15964936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gyrolab Immunoassays: Miniaturization, Automation, and Integration into a Rapid Workflow.
    Engström J
    Methods Mol Biol; 2023; 2612():109-127. PubMed ID: 36795363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of an amplified luminescent proximity homogeneous immunoassay kit for detecting human hepatitis B virus e antibody].
    Ma Q; He A; Dong ZN; Liu TC; Zou LP; Lin GF; Li M; Wu YS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):810-2. PubMed ID: 21602130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies.
    Goodman J; Agoram B
    Bioanalysis; 2013 Dec; 5(23):2919-31. PubMed ID: 24295118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.
    Huang L; Li L; Tien C; LaBarbera DV; Chen C
    Sci Rep; 2019 Jan; 9(1):301. PubMed ID: 30670786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing.
    Mora J; Given Chunyk A; Dysinger M; Purushothama S; Ricks C; Osterlund K; Theobald V
    AAPS J; 2014 Nov; 16(6):1175-84. PubMed ID: 25193269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging technologies to increase ligand binding assay sensitivity.
    Fischer SK; Joyce A; Spengler M; Yang TY; Zhuang Y; Fjording MS; Mikulskis A
    AAPS J; 2015 Jan; 17(1):93-101. PubMed ID: 25331105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an amplified luminescent proximity homogeneous assay for quantitative determination of hepatitis B surface antigen in human serum.
    Liu TC; Huang H; Dong ZN; He A; Li M; Wu YS; Xu WW
    Clin Chim Acta; 2013 Nov; 426():139-44. PubMed ID: 24064424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A homogeneous and noncompetitive immunoassay based on the enhanced fluorescence resonance energy transfer by leucine zipper interaction.
    Ohiro Y; Arai R; Ueda H; Nagamune T
    Anal Chem; 2002 Nov; 74(22):5786-92. PubMed ID: 12463362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.